SCHEMBL24036741

SCHEMBL24036741

COC(=O)C[C@H](N[S@+]([O-])C(C)(C)C)c1cccc(OC(F)F)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.38
MEP1B Q16820 1/20 0.37
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
MAPT P10636 3/20 0.36
RAB9A P51151 2/20 0.36
NPC1 O15118 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PKM P14618 1/20 0.35
KCNA5 P22460 2/20 0.35
KCNK2 O95069 1/20 0.35
KCNH2 Q12809 1/20 0.35
KCNB1 Q14721 1/20 0.35
ROCK2 O75116 1/20 0.34
ROCK1 Q13464 1/20 0.34
LMNA P02545 2/20 0.34
NPSR1 Q6W5P4 3/20 0.33
EPHX2 P34913 1/20 0.33
ACACB O00763 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25753665 1.00 KDM4E (0.38) KDM4EMEP1BMEN1KMT2AMAPT
SCHEMBL25753641 0.91 EPHX2 (0.32) KDM4EMAPTPKMEPHX2HTT
SCHEMBL24036536 0.91 EPHX2 (0.32) KDM4EMAPTPKMEPHX2HTT
SCHEMBL25623352 0.90 GPR139 (0.40) RAB9ANPC1
SCHEMBL25752834 0.88 PKM (0.39) MEN1KMT2AMAPTRAB9AL3MBTL1
SCHEMBL25623356 0.88 KCNA5 (0.37) MAPTRAB9AKCNA5
SCHEMBL25753690 0.88 PKM (0.39) MEN1KMT2AMAPTRAB9AL3MBTL1
SCHEMBL25753667 0.88 KCNA5 (0.37) MAPTRAB9AKCNA5
SCHEMBL24036896 0.86 MEN1 (0.32) MEN1KMT2AMAPTRAB9ALMNA
SCHEMBL24036884 0.86 BACE1 (0.31) MEN1KMT2AEPHX2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192661-A1 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE UBE CORPORATION (JP) 2023-06-22 US disclosed
US-20230192661-A1 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE UBE CORPORATION (JP) 2023-06-22 US disclosed
WO-2023085396-A1 PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME UBE株式会社 2023-05-19 WO disclosed
WO-2021230325-A1 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE 宇部興産株式会社 2021-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192661-A1 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE DHFR, DPYD, CYP2D6 KDM4E 1887/4885MEP1B 2099/4885MEN1 431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.